Showing results (21-30 of 30) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Breast Cancer Research and Treatment|December 1, 1993
Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancerD K Armstrong, J H Fetting, N E Davidson, et al.Psychosomatic Medicine|November 1, 1992
Noradrenergic activity in anticipatory nauseaJ H Fetting, M E Stefanek, V R Sheidler, et al.Cancer Treatment Reports|November 1, 1985
Tastes associated with parenteral chemotherapy for breast cancerJ H Fetting, P M Wilcox, V R Sheidler, et al.Cancer|March 26, 1999
Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinomaB Mikhak, M Zahurak, M D Abeloff, et al.Cancer Chemotherapy and Pharmacology|May 13, 1999
A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancerS Subramanyan, M D Abeloff, S E Bond, et al.Cancer Investigation|January 1, 1997
The effect of aging on the utilization of chemotherapy for metastatic breast cancer: a population-based studyJ H Fetting, G W Comstock, S Eby, et al.Cancer Investigation|August 3, 2000
A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancerE C Dees, S O'Reilly, S N Goodman, et al.Journal of the National Cancer Institute|April 4, 1990
Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancerM D Abeloff, R A Beveridge, R C Donehower, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1996
Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical OncologyC L Bennett, T J Smith, J C Weeks, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup studyJ H Fetting, R Gray, D L Fairclough, et al.Pageof 3